• N-MYC/eIF4G1 Axis Regulates Survival in inv(16) AML Cells

  2026-07-22

  This article reviews recent findings demonstrating that N-MYC, via eIF4G1, is essential for the survival of inv(16) acute myeloid leukemia (AML) cells. The work identifies a previously unrecognized MYCN enhancer and a novel oncogenic role for eIF4G1, providing mechanistic insight and a rationale for targeting this axis in AML therapy.

• NAT10-Driven N4-Acetylcytidine Modulates Oocyte Maturation

  2026-07-22

  This study uncovers the essential role of NAT10-mediated N4-acetylcytidine (ac4C) in the post-transcriptional regulation of mouse oocyte maturation in vitro. The findings reveal that ac4C levels, governed by NAT10, influence meiotic progression and identify TBL3 as a candidate ac4C-binding protein, offering new insight into epitranscriptomic control of reproductive cell fate.

• Letrozole: Mechanistic Insight and Strategy for Translationa

  2026-07-21

  This thought-leadership article explores Letrozole’s unique mechanistic action as a non-steroidal aromatase inhibitor, integrating molecular detail with translational research guidance. Drawing on clinical and laboratory evidence, it situates Letrozole within the evolving landscape of breast cancer research, critically compares it with SERMs like toremifene, and delivers actionable recommendations for protocol design, biomarker analysis, and experimental reproducibility.

• Pharmacokinetic Variability of CSBTA in MASH Mouse Models

  2026-07-21

  This study elucidates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetic and tissue distribution profiles of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice. Its findings reveal that both disease state and repeated dosing significantly modulate systemic and hepatic exposure of key alkaloids via CYP450 enzymes and transporter changes, providing a basis for optimizing dosing strategies in MASLD/MASH research.

• ATRX Loss Sensitizes High-Grade Glioma to RTK and PDGFR Inhi

  2026-07-20

  This study demonstrates that ATRX-deficient high-grade glioma cells are uniquely sensitive to receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. Incorporating ATRX mutation status could refine therapeutic strategies and clinical trial interpretation in glioma research.

• Erastin: Validated Ferroptosis Inducer for Cancer Biology Re

  2026-07-20

  Erastin is a rigorously validated ferroptosis inducer that selectively triggers iron-dependent, non-apoptotic cell death in RAS- or BRAF-mutant tumor cells. Its unique mechanism and reproducibility make it a benchmark tool for ferroptosis research and oxidative stress assays.

• Translating BTK Inhibition: Ibrutinib (PCI-32765) in B-Cell

  2026-07-19

  This thought-leadership article examines how Ibrutinib (PCI-32765) enables precise dissection of B-cell receptor signaling and its translational impact in disease models. It synthesizes mechanistic rationale, workflow optimization, and future outlook for researchers navigating the evolving landscape of B-cell–driven pathology.

• Doxorubicin-Induced Cardiotoxicity: Mechanisms and Mitigatio

  2026-07-18

  Explore how Doxorubicin, a leading cancer chemotherapy drug, induces cardiotoxicity and the latest research-driven strategies to mitigate these effects without compromising anticancer efficacy. This article provides deep scientific insights and actionable guidance for oncology researchers.

• Erastin: Precision Ferroptosis Inducer for Advanced Cancer B

  2026-07-17

  Erastin stands out as a selective ferroptosis inducer, enabling precise dissection of oxidative cell death in RAS/BRAF-mutant tumors. This article delivers actionable workflows, troubleshooting guidance, and context from the latest research, unlocking new dimensions in ferroptosis and cancer biology research.

• Tunicamycin: Precision N-Glycosylation Inhibitor for ER Stre

  2026-07-17

  Tunicamycin stands out as the gold-standard N-glycosylation inhibitor for dissecting ER stress and inflammation pathways in cellular and animal models. With robust support from recent research and supplier-backed reproducibility, this compound enables researchers to probe mechanisms of inflammation suppression, chaperone induction, and gene expression modulation with quantitative precision.

• Hepatic sEH Regulates Osteoclastogenesis via Nrf2 in Osteopo

  2026-07-16

  A recent study uncovers how hepatic soluble epoxide hydrolase (sEH) drives osteoclast differentiation and bone loss by suppressing the Nrf2 antioxidant pathway, revealing a novel liver-bone axis in osteoporosis. These findings provide mechanistic insights into epoxyeicosatrienoic acids metabolism and suggest new avenues for intervention using sEH inhibitors.

• CCK-8 Antagonism of Electroacupuncture Analgesia and Toleran

  2026-07-16

  The reference study by Han et al. uncovers how cholecystokinin octapeptide (CCK-8) antagonizes opioid-mediated analgesia induced by electroacupuncture (EA) in rats, and establishes a mechanistic link between endogenous CCK-8 release and the development of EA tolerance. These findings provide a critical foundation for understanding anti-opioid signaling in pain modulation and have implications for designing experiments on analgesia tolerance and opioid cross-reactivity.

• Cell Counting Kit-8 (CCK-8): Precision Assay for Next-Gen Ca

  2026-07-15

  Explore how Cell Counting Kit-8 (CCK-8) advances cell viability measurement in modern cancer research. This article details unique workflow integration with programmable nanodevices, surpassing standard cytotoxicity assays.

• BMX Kinase Regulates Lysosomal Acidification in Mtb Infectio

  2026-07-15

  This study uncovers how Mycobacterium tuberculosis (Mtb) manipulates host cell survival by exploiting BMX kinase to phosphorylate the V-ATPase E1 subunit (ATP6V1E1), thereby suppressing lysosomal acidification and promoting intracellular persistence. The elucidation of this BMX-dependent mechanism highlights a novel axis of host-pathogen interaction and suggests BMX kinase as a potential therapeutic target in tuberculosis and related infectious diseases.

• SN-38 and Camptothecin Block FUBP1-FUSE Binding in Cancer Mo

  2026-07-14

  This study uncovers that camptothecin and its analog SN-38 not only inhibit DNA topoisomerase I but also prevent the oncogenic regulator FUBP1 from binding to its DNA target FUSE. These dual actions suggest new mechanistic insights for advanced colon and liver cancer research, particularly in tumors overexpressing FUBP1.

13031 records 1/869 page Next 12345 下5页 Last page